NASDAQ:NBIX

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

$96.26

-0.79 (-0.81%)

(As of 03/27/2023 12:27 PM ET)

Add

Compare

Today's Range: $95.78
▼
$97.30
50-Day Range: $94.11
▼
$111.36
52-Week Range: $75.25
▼
$129.29

Volume: 209,271 shs
Average Volume: 828,373 shs
Market Capitalization: $9.30 billion

P/E Ratio: 62.92
Dividend Yield: N/A
Price Target: $125.65

Institutional Ownership

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 30.5% Upside
$125.65 Price Target
Short Interest: Healthy
2.76% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.61
Upright™ Environmental Score
News Sentiment: 1.15
Based on 8 Articles This Week
Insider Trading: Acquiring Shares
$39.03 M Bought Last Quarter
Proj. Earnings Growth: 70.76%
From $2.77 to $4.73 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.19 out of 5 stars

Medical Sector

9th out of 995 stocks

Biological Products, Except Diagnostic Industry

2nd out of 166 stocks

4.3

Analyst's Opinion

Consensus Rating
Neurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 10 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $125.65, Neurocrine Biosciences has a forecasted upside of 30.5% from its current price of $96.28.
Amount of Analyst Coverage
Neurocrine Biosciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
2.76% of the outstanding shares of Neurocrine Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Neurocrine Biosciences has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Neurocrine Biosciences has recently increased by 5.12%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Neurocrine Biosciences does not currently pay a dividend.
Dividend Growth
Neurocrine Biosciences does not have a long track record of dividend growth.

2.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Neurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.
Environmental Sustainability
The Environmental Impact score for Neurocrine Biosciences is -2.61.

3.4

News and Social Media Coverage

News Sentiment
Neurocrine Biosciences has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Neurocrine Biosciences this week, compared to 4 articles on an average week.
Search Interest
26 people have searched for NBIX on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Neurocrine Biosciences insiders have bought 406.47% more of their company's stock than they have sold. Specifically, they have bought $39,032,821.00 in company stock and sold $7,706,823.00 in company stock.
Percentage Held by Insiders
Only 4.40% of the stock of Neurocrine Biosciences is held by insiders.
Percentage Held by Institutions
92.58% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Neurocrine Biosciences are expected to grow by 70.76% in the coming year, from $2.77 to $4.73 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Neurocrine Biosciences is 62.93, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.83.
Price to Earnings Ratio vs. Sector
The P/E ratio of Neurocrine Biosciences is 62.93, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.34.
Price to Book Value per Share Ratio
Neurocrine Biosciences has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops, and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

March 22, 2023 | markets.businessinsider.com

Citigroup Sticks to Its Buy Rating for Neurocrine (NBIX)

March 21, 2023 | finance.yahoo.com

Neurocrine Biosciences to Present at the Stifel 2023 CNS Days

March 27, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.

March 17, 2023 | americanbankingnews.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $125.65 Consensus PT from Analysts

March 9, 2023 | finance.yahoo.com

Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference

March 8, 2023 | finance.yahoo.com

Neurocrine Biosciences to Participate at Investor Conferences in March

March 5, 2023 | finance.yahoo.com

‘2023 Rally Was a Bull Trap,’ Says Morgan Stanley. But These Stocks Still Have Upside

March 4, 2023 | msn.com

Evercore ISI Group Upgrades Neurocrine Biosciences (NBIX)

March 27, 2023 | Investor Place Media (Ad)

Biden To Unleash "Choke Point" Operation On America?

March 3, 2023 | markets.businessinsider.com

Analyst Expectations for Neurocrine Biosciences's Future

March 3, 2023 | finance.yahoo.com

Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting

March 3, 2023 | investing.com

Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA Capsules in Older and Elderly Patients

March 1, 2023 | benzinga.com

Neurocrine Biosciences Stock (NASDAQ:NBIX), Quotes and News Summary

February 19, 2023 | nasdaq.com

First Week of NBIX April 21st Options Trading

February 14, 2023 | finance.yahoo.com

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

February 9, 2023 | finance.yahoo.com

Neurocrine Biosciences Full Year 2022 Earnings: EPS Misses Expectations

February 8, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Neurocrine (NBIX) and Deciphera Pharmaceuticals (DCPH)

February 8, 2023 | finance.yahoo.com

Investors one-year returns in Neurocrine Biosciences (NASDAQ:NBIX) have not grown faster than the company's underlying earnings growth

February 7, 2023 | finance.yahoo.com

Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference

February 7, 2023 | finance.yahoo.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2022 Earnings Call Transcript

February 6, 2023 | finance.yahoo.com

Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates

February 6, 2023 | finance.yahoo.com

Neurocrine Reports 3,000% Profit Growth, But Shares Unexpectedly Tumble

February 6, 2023 | finance.yahoo.com

If You're in Neurocrine Biosciences Consider Getting Out: Here's Why

February 6, 2023 | msn.com

Neurocrine Biosciences Non-GAAP EPS of $1.24 misses by $0.20, revenue of $412M beats by $3.04M

February 4, 2023 | seekingalpha.com

Ingrezza's Potential To Dominate The Huntington's Chorea Market: A Boost For Neurocrine Investors

February 3, 2023 | seekingalpha.com

Neurocrine Biosciences Q4 2022 Earnings Preview

February 3, 2023 | msn.com

Neurocrine Biosciences Earnings Preview

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings: 2/06/2023
Today: 3/27/2023
Next Earnings (Estimated): 5/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:NBIX
CUSIP: 64125C10
CIK: 914475
Web: www.neurocrine.com
Phone: (858) 617-7600
Fax: 858-617-7602
Employees: 1,200
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $125.65
High Stock Price Forecast: $150.00
Low Stock Price Forecast: $95.00
Forecasted Upside/Downside: +29.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 15 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.53
Trailing P/E Ratio: 63.43
Forward P/E Ratio: 35.04
P/E Growth: N/A
Net Income: $154.50 million
Net Margins: 10.38%
Pretax Margin: 14.37%
Return on Equity: 10.19%
Return on Assets: 7.13%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.70
Quick Ratio: 2.64

Sales & Book Value

Annual Sales: $1.49 billion
Price / Sales: 6.30
Cash Flow: $1.78 per share
Price / Cash Flow: 54.46
Book Value: $17.76 per share
Price / Book: 5.46

Miscellaneous

Outstanding Shares: 96,590,000
Free Float: 92,338,000
Market Cap: $9.37 billion
Optionable: Optionable
Beta: 0.50

Key Executives

Kevin Charles Gorman
Chief Executive Officer & Director

Bill Wilson
Vice President-Information Technology & Operations

Matthew C. Abernethy
Chief Financial Officer

Dimitri E. Grigoriadis
Chief Research Officer

Eiry W. Roberts
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?: 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings or view top-rated stocks.
What is Neurocrine Biosciences' stock price forecast for 2023?: 15 analysts have issued 1 year price objectives for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $95.00 to $150.00. On average, they predict the company's stock price to reach $125.65 in the next year. This suggests a possible upside of 29.5% from the stock's current price.
View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts.
How have NBIX shares performed in 2023?: Neurocrine Biosciences' stock was trading at $119.44 at the start of the year. Since then, NBIX stock has decreased by 18.7% and is now trading at $97.05.
View the best growth stocks for 2023 here.
When is Neurocrine Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our NBIX earnings forecast.
How were Neurocrine Biosciences' earnings last quarter?: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its earnings results on Monday, February, 6th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.15 by $0.09. The company earned $412 million during the quarter, compared to analysts' expectations of $408.96 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 10.19% and a net margin of 10.38%. Neurocrine Biosciences's revenue was up 32.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.08) EPS.
What ETFs hold Neurocrine Biosciences' stock?: ETFs with the largest weight of Neurocrine Biosciences (NASDAQ:NBIX) stock in their portfolio include Psyk Etf (PSYK), iShares Neuroscience and Healthcare ETF (IBRN), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), Invesco Dynamic Biotechnology & Genome ETF (PBE), Invesco S&P MidCap Momentum ETF (XMMO), WisdomTree U.S. Growth & Momentum Fund (WGRO) and Invesco S&P MidCap 400 Pure Growth ETF (RFG).
What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?: 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).
What is Neurocrine Biosciences' stock symbol?: Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."
Who are Neurocrine Biosciences' major shareholders?: Neurocrine Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (2.26%), Avidity Partners Management LP (1.85%), Renaissance Technologies LLC (1.68%), Price T Rowe Associates Inc. MD (1.48%), Geode Capital Management LLC (1.44%) and Brown Advisory Inc. (1.10%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Neurocrine Biosciences Inc, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends.
How do I buy shares of Neurocrine Biosciences?: Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Neurocrine Biosciences' stock price today?: One share of NBIX stock can currently be purchased for approximately $97.05.
How much money does Neurocrine Biosciences make?: Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $9.37 billion and generates $1.49 billion in revenue each year. The company earns $154.50 million in net income (profit) each year or $1.53 on an earnings per share basis.
How many employees does Neurocrine Biosciences have?: The company employs 1,200 workers across the globe.
How can I contact Neurocrine Biosciences?: Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 3/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

Neurocrine Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

NBIX Stock News Headlines

NBIX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

NBIX Stock - Frequently Asked Questions

Overall MarketRank^™